Abstract: A humanized antibody specifically recognizing human CA IX, and to therapeutic and diagnostic methods utilizing this antibody is disclosed. The methods relate in particular to treatment or diagnosis of cancers selected from squamous cell carcinoma, myeloma, small-cell lung cancer, non-small cell lung cancer, glioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal (tract) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, mesothelioma, and head and neck cancer.

Abstract: A humanized antibody specifically recognizing proteoglycan domain of human CA IX, and to therapeutic and diagnostic methods utilizing this antibody is disclosed. The methods relate in particular to treatment or diagnosis of cancers selected from squamous cell carcinoma, myeloma, small-cell lung cancer, non-small cell lung cancer, glioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal (tract) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, mesothelioma, and head and neck cancer.

Abstract: Herein disclosed is an alternatively-spliced [AS] variant of MN/CA9 mRNA and its related protein—AS MN/CA IX. Unlike the tumor-associated, full-length [FL] MN/CA9 mRNA and FL MN/CA IX, which in most tissues signify oncogenesis and/or hypoxia, the AS MN/CA9 mRNA is constitutively-expressed under normoxia and is not stimulated by hypoxia, and the AS MN/CA IX is not confined to the cell membrane. Provided herein are diagnostic/prognostic methods for preneoplastic/neoplastic disease to differentiate between AS and FL MN/CA9 expression, and probes, primers, and antibodies useful in such methods. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, which methods are based on the ability of AS MN protein (AS MN/CA IX) to interfere with the catalytic activity of FL MN protein (FL MN/CA IX); such methods may also use AS MN protein fragments that have that interference capability.